/

Elicera in brief Board Management Advisors Elicera's history

Immuno-oncology

What is immuno-oncology?
Oncolytic virus CAR T-cell therapy

CAR T-cell therapy Challenges Mode-of-action Scientific publications

Pipeline ELC-100 ELC-201 ELC-301 ELC-401 Clinical trials Patent portfolio

Press Releases Corporate Governance the Share Financial Reports Financial Calendar Events IPO Analyst Coverage

News Press Releases

/

Financial Calendar

Year-End Report: 2022-01-25
Annual General Meeting: 2022-03-07
Q1-report: 2022-04-26
Q2-report: 2022-08-22
Q3-report: 2022-11-18
Year-End Report: 2023-02-17

Test tubes in a lab environment

Elicera Therapeutics AB is a clinical stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments.

Org.nr: 556966-4955

Elicera Therapeutics AB (publ)
World Trade Center Göteborg
Mässans gata 10, floor 7
412 51, Göteborg
info@elicera.com
+46 (0)70-331 90 51‬

Follow us:

Integrity Policy

By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our Integrity policy.